Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology

“…This decline will be further accelerated by the recent impressive improvement of efficacy of treatments for HCV chronic infection. Recent trials have shown that the current available interferon-free therapeutic regimens with the new direct-acting antiviral agents (DAAs) reach the sustained virological response in more than 90% of patients with cirrhosis, either naïve, relapsers or null responders to Interferon-based regimes, both HCV-monoinfected [30][31][32][33] and HCV/HIV coinfected [34][35][36]. A further impressive reduction of HCV-related mortality rate for liver cirrhosis is expected by a larger use of second and third generation DAAs.…”

Hepatitis C virus infection in children and adolescents

“…Ever‐evolving treatment regimens are available that reliably achieve a >95% “real‐world” cure rate for all HCV genotypes 6. Efficacy has also been demonstrated in historically difficult to treat populations, such as patients with pretreatment cirrhosis, renal disease, patients previously exposed to antiviral therapy, prior null responders, those with HIV co‐infection, and patients following liver transplantation 95, 96, 97, 98, 99…”

Current and future challenges in HCV: insights from an Italian experts panel

“…Treatment-naïve and treatment-experienced patients infected with subtype 1b as well as treatment-naive patients infected by genotype 4 should receive this combination for 12 weeks without ribavirin; treatment should be prolonged to 16 weeks with the addition of ribavirin in genotype 1a patients with higher viral load (≥ 800,000 IU/mL) or with baseline NS5A RASs conferring resistance to elbasvir, as well as in genotype 4 treatment-experienced patients with higher viral load (≥ 800,000 IU/mL) [14,19,54,[68][69][70][71][72]. C-SALVAGE examined the use of elbasvir/grazoprevir plus R ribavirin BV in patient with chronic HCV genotype 1 infection (cirrhotic and non-cirrhotic patients) after failure of peg-IFN and ribavirin [69].…”